Tirzepatide
FDA ApprovedTirzepatide (LY3298176)
- Category
- Weight Loss & Metabolism
- Aliases
- Mounjaro, Zepbound, LY3298176
- Administration
- Subcutaneous injection (once weekly)
Documented side effects
Tier 1 · Peer-reviewed / regulatoryNausea
A common digestive side effect, often most noticeable when starting or increasing the dose.
Vomiting
A gastrointestinal side effect that can accompany nausea, particularly early in treatment.
Diarrhea
A gastrointestinal side effect commonly reported with this class of compound.
Rare pancreatitis risk
A small but serious risk of pancreas inflammation exists with this class of compound.